AcelRx Baffled By Zalviso Trial Request On Opioid Dispensing Problems
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA asked for clinical study before reviewing data AcelRx generated after previous ‘complete response,’ CEO King said.
You may also be interested in...
AcelRx's Sublingual Opioid Dsuvia Brings Unique Risk To Advisory Panel: Dropped Tablets
US FDA appears generally satisfied that AcelRx fulfilled initial safety concerns cited in October 2017 complete response letter.
Keeping Track: A CRL For Tlando, An Accelerated Approval For AndexXa, And A Burst Of Supplemental Approvals
The latest US drug development news and highlights from our Performance Tracker.
Keeping Track: FDA Hands Out Complete Responses, Expedited Pathway Designations
The latest US drug development news and highlights from our Performance Tracker.